Summer 2026
Posted on 5/2/2026
Designs and manufactures tubeless insulin pumps
No salary listed
No H1B Sponsorship
Acton, MA, USA
In Person
Onsite in Acton, MA; travel to local suppliers up to 5%.
Bachelor's
See people who can refer or advise you
Insulet develops and manufactures insulin delivery devices for people with diabetes, led by the Omnipod tubeless, waterproof insulin pump system. The pod is worn on the body to deliver insulin under the skin, and is controlled wirelessly by a personal diabetes manager; Omnipod 5 adds automated insulin delivery that adjusts dosing using CGM data. The key differences are a tubeless, tubing-free design and ongoing updates that integrate automated dosing with CGMs, supported by a global manufacturing and distribution network. The goal is to simplify diabetes management with easy-to-use, flexible insulin delivery and automated dosing that fit users’ daily lives.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Acton, Massachusetts
Founded
2000
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Remote Work Options
Insulet reported second quarter revenue of $801.7 million, beating analyst estimates by 1.9% with 23.5% year-on-year growth. Adjusted EPS of $1.66 also exceeded expectations by 14.3%. However, the company's shares fell sharply as CEO Ashley McEvoy acknowledged lower-than-expected retention rates among new type 2 diabetes users. "We should have identified the issue sooner," McEvoy stated. Third quarter revenue guidance of $833.4 million came in below analyst estimates of $847.3 million. Operating margin declined to 16.2% from 18.7% in the prior year period. During the earnings call, analysts pressed management on type 2 diabetes trends and retention challenges. McEvoy pointed to the segment's size and unmet need, whilst COO Eric Benjamin cited early positive data from pilot programmes and the Omnipod Discover product.
Insulet faces securities suit: investors weigh options. Insulet: navigating choppy legal waters. Insulet Corporation, known among traders as PODD, has found itself staring down the barrel of a securities class action lawsuit. This isn't just some frivolous affair that'll drift away on the next breeze. Investors Hangout, LLC has got allegations flying around about violations of the big guns - Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Toss in Rule 10b-5, and it's time to pop an aspirin, because this ride isn't for the faint-hearted. The accusations and what's at stake. Here's the crux: The complaint accuses Insulet of spinning a tale, one that might've pulled the wool over quite a few market eyes. There are claims they bungled their manufacturing processes, risking customer safety. Misleading? Potentially. Dangerous? Very possibly, yes. All this from February 21, 2025 to May 26, 2026, a period that's now under the legal microscope. With potential safety implications hanging in the balance, investors aren't taking these claims lightly. Imagine buying into a company that can't keep a steady grip on its manufacturing line. Not the kind of stock you wanna be caught holding the bag on, right? Investor actions: clock's ticking. If you laid your money down on PODD within the class period, there's a chance to step into the ring. The folks over at DJS Law Group are rallying the troops, with a deadline of August 31, 2026, dangling out there for potential lead plaintiff appointments. It's the kind of legal play where being proactive beats sitting on your thumbs. Why partner with DJS Law Group? These guys aren't messing around - they specialize in this sort of legal pugilism: securities class actions, heavyweight corporate governance cases, and, of course, those juicy M&A lifts. Let's be clear, Insulet might've slept on some controls, but you don't sleep on a firm whose clients include heavyweight hedge funds and alternative asset managers. Where do investors go from here? For the top dogs on Wall Street, a lawsuit like this signals more than a skirmish - it's an all-out conflict with significant implications. Shareholders need to keep their eyes peeled and ears open, considering all options on the table. Are Investors Hangout, LLC talking settlement somewhere down the road? Could be. Or maybe it drags on, forcing corrective actions and muddying Insulet's financial waters further. In these moments, due diligence isn't just a fancy phrase; it's the difference between cutting losses or potentially compounding them. Traders who've weathered the storm before know that while downturns sink some ships, they're golden opportunities for others. The final countdown. In the tumultuous world of trading, today's bloodbath might be tomorrow's blue sky. August 31, 2026, isn't just a date; it's an ultimatum - decide whether to dive in or step back. So, keep your brokerage accounts handy and your lawyer's number closer. The curtain's lifting on this legal showdown, and you better be ready to play your part in this high-stakes drama.
Insulet has lowered its 2026 revenue growth forecast to 20%-22% from 21%-23%, citing slower US sales of its Omnipod insulin pumps. Shares fell more than 12% in pre-market trading. The medical device maker cut its US Omnipod sales growth forecast to 17%-19% from 20%-22%, whilst raising its international forecast to 30%-32% from 26%-28%. CEO Ashley McEvoy said the outlook reflects learnings from scaling in type 2 diabetes. Second-quarter results beat expectations, with revenue rising 23.5% to $801.7 million and adjusted profit of $1.66 per share. Quarterly Omnipod sales increased 24.6% to $795.9 million. Analysts expressed concern about competitive pressures affecting future growth rates.
Insulet Corporation reported second quarter 2026 revenue of $802 million, up 23.5% year-over-year and 22.7% in constant currency, exceeding its guidance range of 20-22% at constant currency rates. Total Omnipod revenue reached $795.9 million, rising 24.6%. US Omnipod revenue increased 20.1% to $544.1 million, whilst international Omnipod revenue grew 35.5% to $251.8 million. The company posted net income of $95.0 million, or $1.37 per diluted share, compared to $22.5 million in the prior year. Adjusted net income was $115.0 million, or $1.66 per diluted share, up 37.4%. Insulet launched Omnipod 5 in Spain, marking the 26th country for Omnipod sales and the 20th for Omnipod 5 availability. The company also expanded its product ecosystem with a next-generation algorithm and compatibility with Abbott's FreeStyle Libre 3 Plus sensor.
$PODD securities: suffer losses on your Insulet investment? BFA Law reminds investors of the Securities Fraud lawsuit to recover losses. A securities fraud class action lawsuit has been filed on behalf of Insulet investors after its stock plummeted over 6% because of misrepresentation about the safety of Insulet's Omnipod products. NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Insulet Corporation (NASDAQ:PODD) and certain of the Company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws. If you invested in Insulet, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/insulet-class-action-lawsuit. Key Details of the Insulet ($PODD) Class Action: * Lead Plaintiff Deadline: August 31, 2026 * Alleged Misconduct: Securities fraud relating to the safety of Insulet's Omnipod products * Largest Alleged Stock Drop: March 12, 2026 - 6.88% Stock Drop * Court: U.S. District Court for the District of Massachusetts * Take Action: Contact BFA Law to discuss your rights Insulet investors have until August 31, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Insulet securities. The class action is pending in the U.S. District Court for the District of Massachusetts. It is captioned Hu v. Insulet Corporation et al., No. 26-cv-13062. Why is Insulet Being Sued for Securities Fraud? Insulet is primarily engaged in the development, manufacture, and sale of insulin delivery systems for people with insulin-dependent diabetes through its Omnipod platform. The Omnipod platform includes: the Omnipod(R) 5 Automated Insulin Delivery System ("Omnipod 5"), the Omnipod DASH(R) Insulin Management System ("Omnipod DASH"), and the Omnipod Insulin Management System ("Omnipod Eros"). Throughout the relevant period, Insulet misrepresented the safety of its Omnipod products as well as its ability to efficiently produce "medical grade quality at consumer electronic scale." In reality, certain of Insulet's products suffered from undisclosed manufacturing defects that put patient safety at risk. Why did Insulet's Stock Drop? On March 12, 2026, Insulet disclosed that a manufacturing issue with its Omnipod(R) 5 Pods caused a "tear in the internal tubing that delivers insulin" resulting in insulin being released inside the Pod "instead of being fully infused into the body as intended." Accordingly, Insulet "initiated a voluntary Medical Device Correction for specific lots of Omnipod(R) 5 Pods." This news caused the price of Insulet stock to drop $16.23 per share, or 6.88%, from a closing price of $236.07 per share on March 12, 2026, to $219.84 per share on March 13, 2026. On May 26, 2026, Insulet announced another voluntary Medical Device Correction due to a manufacturing issue, this time to its Omnipod 5, Omnipod DASH, and Omnipod Eros systems. It again indicated that the manufacturing issue resulted in a tear in the tubing which "could result in insulin under-delivery." This news caused the price of Insulet stock to drop $7.79 per share, or 5.07%, from a closing price of $218.11 per share on May 26, 2026, to $146.01 per share on May 27, 2026. What Can You Do? If you invested in Insulet, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named "Elite Trial Lawyers" by the National Law Journal, "Litigation Stars" by Benchmark Litigation, among the top "500 Leading Plaintiff Financial Lawyers" by Lawdragon, "Titans of the Plaintiffs' Bar" by Law360 and "SuperLawyers" by Thomson Reuters. Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff's securities litigation law firm, with clients noting: "[t]here is no better service provider in the practice area," "[t]he interest of the client is always front and center," and "[t]here isn't a better firm in this space." One testimonial described the firm as "nimble and entrepreneurial," with a "relentless focus on adding value for clients." Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. Attorney advertising. Past results do not guarantee future outcomes. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Today in New York do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.